#	Pagina
attuale pagina	/open-h2020/projects/218885/index.html
-1	/open-consip/fornitori/2019/profilo-01996810063/index.html
-2	/open-consip/fornitori/2020/profilo-01479370932/index.html
-3	/open-h2020/projects/225870/index.html
-4	/open-h2020/projects/227672/index.html
-5	/open-h2020/projects/209254/index.html
-6	/open-consip/fornitori/2014/profilo-01471360709/index.html
-7	/open-h2020/projects/194135/index.html
-8	/open-dormire/veneto/PADOVA/CITTADELLA/ALBERGO/4/index.html
-9	/open-consip/fornitori/2020/profilo-00979490117/index.html
-10	/open-h2020/projects/211120/index.html

Opendata, web and dolomites

NEFERTITI SIGNED

NEFERTITI: A Novel Eco-Friendly, dually Efficient and Resistance-free Treatment of vaginITIs

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

NEFERTITI project word cloud

Explore the words cloud of the NEFERTITI project. It provides you a very rough idea of what is the project "NEFERTITI" about.

biggest limited overconsumption drug discomfort antimicrobials substance preclinical gardnerella tablet disrupts natural vaginal delta treat bv gedea least socioeconomic commercialization globally mechanism curative contains incidence infections reduce rate fungus biofilm heavy adversely keep prolonged causes lies plan switches vulvovaginal burden global threats vaginosis restores eliminate benign life vcc bay close bacteria clinical recurrent misdiagnosis removed normally commercialisation yeast preventative ph health relapse guide 450 prepare date treatment caused unmet candidiasis gap market resistance candida antibiotic efficacy sme validation form million performed trial phyph gda bacterial discharge treatments causing road healthy antibiotics business supports instrument glucono quality antifungals free lactone

Project "NEFERTITI" data sheet

The following table provides information about the project.

Coordinator	GEDEA BIOTECH AB Organization address address: MEDICON VILLAGE SCHEELEVAGEN 2 city: LUND postcode: 223 81 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Sweden [SE]
Project website	http://gedeabiotech.com/
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-1
Funding Scheme	SME-1
Starting year	2018
Duration (year-month-day)	from 2018-12-01 to 2019-05-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	GEDEA BIOTECH AB GEDEA BIOTECH AB Organization address address: MEDICON VILLAGE SCHEELEVAGEN 2 city: LUND postcode: 223 81 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (LUND)	coordinator	50˙000.00

Map

Project objective

This project will develop a business plan to guide clinical validation and commercialization of pHyph, a novel treatment targeting vaginal yeast and bacterial infections. Bacterial vaginosis (BV) and vulvovaginal candidiasis (VCC) are common vaginal infections caused by bacteria (often Gardnerella) or yeast (a fungus) called Candida. 450 million globally experience at least 4 vaginal bacteria or Candida infections each year. It causes significant discomfort, adversely affects quality of life and is associated with heavy socioeconomic burden. To date, all treatments are limited to antifungals and antibiotics that show low efficacy and high relapse rate. With prolonged usage, misdiagnosis, and overconsumption, there is a high incidence of drug resistance, which the WHO considered one of the biggest threats to global health. Gedea has developed a vaginal tablet that contains the natural substance Glucono-δ-lactone (GDA), which switches Candida towards a benign yeast form, restores vaginal pH and disrupts the Candida and bacteria biofilm without causing treatment resistance. The yeast is removed through vaginal discharge. Since this is an antibiotic-free treatment, healthy bacteria that normally keep Candida at bay are also not removed and therefore a low relapse rate is expected with the use of pHyph. The product’s key feature lies in its ability to treat both yeast and bacterial infections and its use as both a preventative and curative treatment. These features are unmet by any other product on the market. Preclinical research performed to date strongly supports pHyph’s novel mechanism to treat vaginal infections, reduce recurrent infections and eliminate the need for antibiotics/antimicrobials. The proposed project will further prepare pHyph for a clinical trial. SME Instrument funding will allow Gedea to close the gap on the road towards commercialisation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEFERTITI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEFERTITI" are provided by the European Opendata Portal: CORDIS opendata.